ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

NCI contract Awards; RFPs Available; RFAs, PA Available.

October 14, 1994

Peters Leaves NCI For CF Foundation

February 3, 1978

DCPC Begins Reassessment of Year 2000 Goals; Advisors Discuss A ‘More Dynamic Model’

May 22, 1992

In Brief: NCAB to Hear Report On Treatment Programs, Discuss Hogness Plan For New Type of Review

November 3, 1978

Appropriations Committees Lean Toward Adding Some To NCI Budget; ACS To Ask Again For $1.5 Billion

April 20, 1984

Self-Collected Pap Smear Tests Could Advance HPV Screening

January 27, 2012